StAR related lipid transfer domain containing 5Genealiases: []
Q-omics provides the consensus-scored STARD5 profile across patient tissues and cancer cell-line models. STARD5 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, STARD5 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, STARD5 protein abundance shows 21,002 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight LUAD, and HNSC as cancer lineages where STARD5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STARD5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STARD5 survival associations across molecular data types. STARD5 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STARD5 RNA expression–survival associations across cancer types. High STARD5 expression shows unfavorable associations in HNSC, but favorable associations in LUAD, LIHC, BRCA, SARC and PAAD. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for STARD5 RNA expression.
This table summarizes STARD5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for STARD5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STARD5 shows lower tumor expression in LIHC, UCEC and COAD and higher tumor expression in HNSC, KIRC and LUSC. The HNSC box plot shows higher STARD5 RNA expression in tumor versus normal tissue (log2 FC = +0.685, t-test p < 0.001).
This table shows molecular features associated with STARD5 in patient tissues and cancer cell lines. In patient samples, STARD5 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, STARD5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
